Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 34, No. 1, 2005
Issue release date: November 2005
Section title: Original Paper
Pathophysiol Haemos Thromb 2005;34:6–12

Long-Term Prospective Study of Recurrent Venous Thromboembolism in Patients Younger than 50 Years

García-Fuster M.-J.a · Forner M.-J.a · Fernández C.a · Gil J.b · Vaya A.c · Maldonado L.b
aService of Internal Medicine and bService of Radiology, Hospital Clínico Universitario, cThrombosis and Haemostasis Unit, Hospital La Fe, Valencia, Spain
email Corresponding Author

María-José García-Fuster, MD

Service of Internal Medicine, Hospital Clínico Universitario

Avda. Blasco Ibáñez 10

ES–46010 Valencia (Spain)

Tel./Fax +34 96 3862647, E-Mail garciafuster_mjo@gva.es


  1. White RH: The epidemiology of venous thromboembolism. Circulation 2003;107:I-4–I-8.
    External Resources
  2. Kearon C: Natural history of venous thromboembolism. Circulation 2003;107:I-22–I-30.
  3. Lamping DL, Schroter S, Kurz X, et al: Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg 2003;37:410–419.
  4. Kahn SR, Hirsch A, Shrier I: Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002;27:1144–1148.
  5. Palareti G, Cosmi B: Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004;11:192–197.
  6. Schulman S, Rhedin AS, Lindmarker P, et al: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661–1665.
  7. Lindmarker P, Schulman S, Sten-Linder M, et al: The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999;81:684–689.
  8. Heit JA, Mohr DN, Silverstein MD, et al: Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761–768.
  9. Cushman M, Tsai A, Heckbert SR, et al: Incidence rates, case fatality, and recurrence rates of deep thrombosis and pulmonary embolus: the Longitudinal Investigation of Thromboembolism Etiology (LITE) (abstract). Thromb Haemost 2001;86(suppl 1): OC2349.
  10. Arcelus JI, Caprini JA, Monreal M, et al: The management and outcome of acute venous thromboembolism: a prospective registry including 4,011 patients. J Vasc Surg 2003;38:916–922.
  11. Prandoni P, Lensing AW, Cogo A, et al: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1–7.
  12. Hansson PO, Sörbo J, Eriksson H: Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769–774.
  13. Patel RK, Ford E, Thumpston J, et al: Risk factors for venous thrombosis in the black population. Thromb Haemost 2003;90:835–838.
  14. Prandoni P, Cogo A, Bernardi E, et al: A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Thromb Haemost 1993;88:1730–1735.
  15. Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med 2002;346:752–763.
  16. García-Fuster MJ, Fernández C, Forner MJ, et al: Risk factors and clinical characteristics at thromboembolic venous disease in young patients: a prospective study. Med Clin (Barc) 2004;123:217–219.
  17. Prandoni P, Cogo A, Bernardi E, et al: A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Thromb Haemost 1993;88:1730–1735.
  18. White RH, Beyth RJ, Zhou H, et al: Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999;107:414–424.
  19. Levine MN, Raskob G, Landefeld S, et al: Hemorrhagic complications of anticoagulant treatment. Chest 2001;119:S108–S121.
    External Resources
  20. Pengo V, Lensing AWA, Prins MH, et al: Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257–2264.
  21. Prandoni P, Lensing AW, Prins MH, et al: Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955–960.
  22. Khamashta MA, Cuadrado MJ, Mujic F, et al: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993–997.
  23. Schulman S, Svenungsson E, Granqvist S: Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332–338.
  24. Ridker PM, Miletich JP, Stampfer MJ, et al: Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800–2802.
  25. Simioni P, Prandoni P, Lensing AW, et al: The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399–403.
  26. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933–938.
  27. Kniffin WD Jr, Baron JA, Barrett J, et al: The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994;154:861–866.
  28. Kyrle PA, Minar E, Bialonczyk C, et al: The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558–2563.
  29. Abdollahi M, Cushman M, Rosendaal FR: Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003;89:493–498.
  30. Ridker PM, Goldhaber SZ, Danielson E, et al: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425–1434.
  31. Schulman S, Wahlander K, Lundstrom T, et al: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713–1721.